Tuesday, November 20, 2018

Physician Tips: Taking the Complexity Out of Liver Test Interpretation

Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highest risk for progressing to end‐stage liver disease. Consequently the degree of liver fibrosis is one of the most important diagnostic and prognostic assessments in chronic liver disease.1

Yet the standard diagnostic tests for early liver disease, short of biopsy, remain less than ideal. (published site)

Wednesday, November 7, 2018

Physician Tips: The silent epidemic of fatty liver disease

For Fibronostics

A growing number of Americans are dying from liver disease and the age at which people are developing it is declining with the greatest increase in people dying of alcoholic cirrhosis and liver cancer since 2009 is among young people aged 25-34.

That’s the findings of a new study published in the July 2018 British Medical Journal. (published site)

Monday, November 5, 2018

What is Non-Alcoholic Steatohepatitis (NASH)?

For Fibronostics

Nonalcoholic steatohepatitis (NASH) is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD), which damages the liver due to a buildup of fat. NASH differs from non-alcoholic fatty liver disease and is characterized by a type of liver cell injury, called hepatocellular ballooning, and inflammation. (published site)

Friday, November 2, 2018

Physician Tips: A practical guide for screening patients for excessive alcohol use

For Fibronostics

Primary care and specialists are always being reminded to screen for risky or abusive behaviors ranging from tobacco, alcohol and drugs, domestic abuse, sexual behaviors and on and on.

As a practical matter, however, primary care physicians have only 15 minutes allotted for any given office visit, most often not enough time to address the problem the patient made the appoint for in the first place. (published site)